PMGC (ELAB) vs GeoVax Labs (GOVX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
GeoVax Labs is the larger company by market cap ($2.9 million vs $2.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ELAB | GOVX |
|---|---|---|
| Share price | $3.13 | $0.2866 |
| Market cap | $2.53M | $2.90M |
| 1-day change | -2.04% | -0.97% |
| EPS (TTM) | $-1,748.36 | $-8.84 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2,671.20 | $15.75 |
| 52-week low | $2.59 | $0.277 |
| Distance from 52-week high | -99.88% | -98.18% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +3389.18% |
| Average volume | 140.44K | 769.87K |
| Shares outstanding | 809.58K | 10.10M |
| Employees | 32 | 19 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About PMGC
ELAB stock →PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of aesthetic medicines and therapeutic products. It operates through three segments: corporate, treasury and biosciences; IT packaging solutions; and precision engineering and machining.
Healthcare · Biotechnology · 32 employees
About GeoVax Labs
GOVX stock →GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine.
Healthcare · Biotechnology · 19 employees
ELAB vs GOVX FAQ
Which is bigger, PMGC or GeoVax Labs?
GeoVax Labs (GOVX) is larger, with a market capitalization of $2.90M compared with $2.53M for PMGC (ELAB).
Are PMGC and GeoVax Labs in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.